Determining the importance of change in the overactive bladder questionnaire.
about
Minimum important difference for validated instruments in women with urge incontinence.The effect of mirabegron on patient-related outcomes in patients with overactive bladder: the results of post hoc correlation and responder analyses using pooled data from three randomized Phase III trialsOnabotulinumtoxinA vs Sacral Neuromodulation on Refractory Urgency Urinary Incontinence in Women: A Randomized Clinical TrialImpact of urinary incontinence on health-related quality of life, daily activities, and healthcare resource utilization in patients with neurogenic detrusor overactivity.Impact of overactive bladder on quality of life and resource use: results from Korean Burden of Incontinence Study (KOBIS).Anticholinergic therapy vs. onabotulinumtoxina for urgency urinary incontinence.Efficacy and safety of venous angioplasty of the extracranial veins for multiple sclerosis. Brave dreams study (brain venous drainage exploited against multiple sclerosis): study protocol for a randomized controlled trial.Efficacy and safety of flexible dose fesoterodine in men and women with overactive bladder symptoms including nocturnal urinary urgency.Combined Tolterodine and Vaginal Estradiol Cream for Overactive Bladder Symptoms After Randomized Single-Therapy TreatmentDiagnostic Tool for Assessing Overactive Bladder Symptoms: Could the International Prostate Symptom Storage Subscore Replace the Overactive Bladder Symptom Score?Patient-reported outcomes and different approaches to urinary parameters in overactive bladder: what should we measure?Mirabegron in overactive bladder: a review of efficacy, safety, and tolerability.Determining clinically important changes in range of motion in patients with Dupuytren's Contracture: secondary analysis of the randomized, double-blind, placebo-controlled CORD I study.Superiority of fesoterodine 8 mg vs 4 mg in reducing urgency urinary incontinence episodes in patients with overactive bladder: results of the randomised, double-blind, placebo-controlled EIGHT trial.Solifenacin treatment in men with overactive bladder: effects on symptoms and patient-reported outcomes.A novel leadless, miniature implantable Tibial Nerve Neuromodulation System for the management of overactive bladder complaints.Correlation of the Overactive Bladder Symptom Score, and the Voiding Diary and Urodynamic Parameters in Patients with Overactive Bladder Syndrome.Impact of symptom improvement on patients' bother and quality of life in female patients with overactive bladder treated by solifenacin (SET-Q).Efficacy and tolerability of solifenacin in patients aged ≥ 65 years with overactive bladder: post-hoc analysis of 2 open-label studies.Efficacy of fesoterodine compared with extended-release tolterodine in men and women with overactive bladder.Refractory urgency urinary incontinence treatment in women: impact of age on outcomes and complications.Impact of urinary incontinence on healthcare resource utilization, health-related quality of life and productivity in patients with overactive bladder.Clinically meaningful improvement on the quality of erection questionnaire in men with erectile dysfunction.Quality of life in patients with overactive bladder: validation and psychometric properties of the Spanish Overactive Bladder Questionnaire-short Form.Mirabegron improves quality-of-life, treatment satisfaction, and persistence in patients with overactive bladder: a multi-center, non-interventional, real-world, 12-month study.Combination treatment with mirabegron and solifenacin in patients with overactive bladder: exploratory responder analyses of efficacy and evaluation of patient-reported outcomes from a randomized, double-blind, factorial, dose-ranging, Phase II studComparison of mirabegron and imidafenacin for efficacy and safety in Japanese female patients with overactive bladder: A randomized controlled trial (COMFORT study).Responder and health-related quality of life analyses in men with lower urinary tract symptoms treated with a fixed-dose combination of solifenacin and tamsulosin oral-controlled absorption system: results from the NEPTUNE study.An overactive bladder symptom and health-related quality of life short-form: validation of the OAB-q SF.The minimum important difference for the Pelvic Organ Prolapse-Urinary Incontinence Sexual Function Questionnaire.Solifenacin for overactive bladder with incontinence: symptom bother and health-related quality of life outcomes.Validation of the urgency questionnaire in Portuguese: A new instrument to assess overactive bladder syndrome.Flexible-dose fesoterodine in elderly adults with overactive bladder: results of the randomized, double-blind, placebo-controlled study of fesoterodine in an aging population trial.Results of a prospective, randomized, multicenter study evaluating sacral neuromodulation with InterStim therapy compared to standard medical therapy at 6-months in subjects with mild symptoms of overactive bladder.Does concomitant anterior/apical repair during midurethral sling improve the overactive bladder component of mixed incontinence?Patient-reported outcomes in patients with overactive bladder treated with mirabegron and tolterodine in a prospective, double-blind, randomized, two-period crossover, multicenter study (PREFER).
P2860
Q30353491-743E6F48-91A3-4BD6-9866-BCA2E5C66D65Q30894093-0B526794-6324-4EBE-9E19-FE127070E547Q33587587-002243AB-E8DF-474F-8E1C-65F266353725Q35141099-9A42BD0C-F022-4ED7-A5A8-771DC0DEE61BQ35780487-335EF612-B924-4111-ADBE-A1695CB5AB18Q36528534-110719DF-B4EA-4C22-8F9E-DD2342620A89Q36597127-BB963DEE-F627-4865-B6A0-54A7E44678FBQ36919948-DD7FEC36-1AE5-4223-8571-DB5BDB9A1E15Q37034036-A522C809-9D4D-4EC6-9492-23B40B22DDFFQ37373384-9562FF72-35BC-4FED-99E3-CE802674D696Q37947438-6CDBDB62-9AD5-41B2-A1E8-E5B7F8D28BF3Q38152756-5989A05E-1ACD-442D-8AAA-757C1C870F6BQ38483599-F3D6D0AD-0342-4E1C-B69F-E900776C34ACQ39211584-7B0C6B50-C228-4306-97A7-81164139D907Q39294461-681EE8A9-38B3-444B-816C-085C9A5F8CB7Q40053845-8190C5B0-456E-4655-A8DD-07E9B1B5D79CQ40215490-282B6CCF-8495-4816-ABEA-E6CB8788F5B8Q42631586-41C9FFEA-7D49-4111-99AC-A6E822FBB0DBQ42688884-922911B6-C37F-4702-8483-8AB54CA8012CQ45041779-D0448D23-B479-42E9-B403-77033589AB1AQ46053170-6F79647D-EC9C-444C-BFAD-CFAB726FB786Q46054511-369A0246-72EC-494C-96CB-F6DE42E762A5Q46110331-3C24505B-3FD3-46A5-88F8-015EF2466AB7Q46208100-0D06C808-DB42-4078-A65F-F15C3AC7B6B5Q47563038-0AA489E6-A389-4731-A22E-B5D7C0702C07Q47677924-A472E1C7-B3D4-4C2B-8C87-FA4E1E9BE5E6Q47991589-D8A6F005-211D-42CA-92C9-4B65A4D87CD6Q48040104-0CCD9EC8-818B-48A0-B630-9386724B4399Q48045519-5B31548A-4F7E-413F-97D6-503399C54D8BQ48085123-5DF27AB7-D274-4777-9F63-225CD7F3AF62Q48475293-6DDB3812-62F0-40E1-99C6-ECE3CBDAA98AQ50014328-B82B537F-5231-400A-9DEE-BF8A3D570874Q50726163-0519797E-01FC-4D2A-B4D7-DA769CB5B405Q51168997-BA0E8D0C-1319-40A3-B96D-4A3742C20301Q53556057-6ABAEFFD-9E3E-473F-A922-7E2FBAA56435Q55359372-0CEB48FF-0A68-47A0-BF0C-BCFAE9518E14
P2860
Determining the importance of change in the overactive bladder questionnaire.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年学术文章
@wuu
2006年学术文章
@zh
2006年学术文章
@zh-cn
2006年学术文章
@zh-hans
2006年学术文章
@zh-my
2006年学术文章
@zh-sg
2006年學術文章
@yue
2006年學術文章
@zh-hant
name
Determining the importance of change in the overactive bladder questionnaire.
@en
Determining the importance of change in the overactive bladder questionnaire.
@nl
type
label
Determining the importance of change in the overactive bladder questionnaire.
@en
Determining the importance of change in the overactive bladder questionnaire.
@nl
prefLabel
Determining the importance of change in the overactive bladder questionnaire.
@en
Determining the importance of change in the overactive bladder questionnaire.
@nl
P2093
P1476
Determining the importance of change in the overactive bladder questionnaire
@en
P2093
Christine L Thompson
Karin S Coyne
Louis S Matza
Vikram Khullar
P304
627-32; discussion 632
P356
10.1016/J.JURO.2006.03.088
P407
P50
P577
2006-08-01T00:00:00Z